• Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
Sign in
Welcome!Log into your account
Forgot your password?
Password recovery
Recover your password
Search
Medicines Law & Policy Research and resources on intellectual property and health
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About

Tag: compulsory licensing for export

Never say never – Why the High Income Countries that opted-out...

Christopher Garrison - April 8, 2020

New Database Documents the Power of TRIPS Flexibilities

Ellen 't Hoen - November 27, 2018

European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to...

Ellen 't Hoen - May 21, 2018

Access to medicines amendment of the WTO TRIPS Agreement. Hype or...

Ellen 't Hoen - April 11, 2017

Recent Posts

  • We need a Global Vaccines Taskforce, not just a British or European one
  • The European Commission says Covid-19 vaccines should be global public goods, but do their agreements with pharma reflect this?
  • The elephant in the room at the WHO Executive Board
  • Wrapping up 2020 with some noteworthy medicines, law and policy events

Posts by Subject

Access to Medicines ARIPO C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Data exclusivity Delinkage DNDi dolutegravir European Commission European Union evergreening Fair Pricing Gilead Hepatitis C HIV IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs Patents PrEP R&D remdesivir Sofosbuvir SPC Supplementary Protection Certificates The Netherlands transparency TRIPS Council TRIPS flexibilities Truvada vaccines WHO WIPO WTO
Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: info@medicineslawandpolicy.net.
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
 This work is licensed under Creative Commons.